Biomarker: K080-IgE Formaldehyde

Overview

K080-IgE Formaldehyde measures immunoglobulin E (IgE) antibodies directed against formaldehyde in a blood sample. Formaldehyde is primarily recognized as an irritant and a cause of allergic contact dermatitis; IgE-mediated sensitization appears to be uncommon in humans. A detectable result may indicate sensitization, but it does not by itself establish that formaldehyde causes a person’s symptoms, and a low or undetectable result does not exclude irritant or delayed contact reactions. Clinical usefulness is therefore limited and depends on a compatible exposure and symptom history.

Clinical Use Cases

Evaluation of suspected rare immediate hypersensitivity reactions after exposure to formaldehyde-containing products, such as some dental materials or disinfectants.
Supporting assessment of suspected IgE-mediated occupational or environmental reactions when the exposure history is strongly suggestive.
Complementing, but not replacing, clinical evaluation, exposure assessment, and other allergy testing.
Research measurement of formaldehyde-specific IgE prevalence and clinical relevance. Human studies have found specific IgE infrequently and generally at low levels.
Differentiating possible IgE-mediated sensitization from more common irritant effects or allergic contact dermatitis, which are not reliably assessed by serum specific IgE testing.

Specimen Types

Serum, collected from venous blood.
Plasma may be accepted by some assay systems, but specimen requirements are method-specific.

Measurement Methods

In-vitro allergen-specific IgE immunoassay using formaldehyde allergen or formaldehyde-associated antigen preparations.
Fluorescence enzyme immunoassay or other solid-phase immunoassay platforms.
Radioallergosorbent test (RAST) or CAP-RAST, used in published human research.
Skin-prick testing may be used by an allergy specialist as a complementary in-vivo assessment, but it is not a measurement of serum K080-IgE.
Patch testing is generally more relevant for suspected formaldehyde allergic contact dermatitis and evaluates delayed hypersensitivity rather than IgE-mediated sensitization.

Test Preparation and Influencing Factors

No fasting or other special preparation is generally required for an allergy blood test.
Tell the clinician about all medications and supplements. Antihistamines can affect skin-prick testing, but they generally do not interfere with serum specific IgE measurement.
Do not discontinue medications unless instructed by the treating clinician.
Results should be interpreted with the timing, route, intensity, and recurrence of formaldehyde exposure and the patient’s symptoms.
A positive result indicates sensitization, not necessarily clinically relevant allergy or symptom causation.
Formaldehyde-related irritation, asthma-like symptoms, and allergic contact dermatitis may occur without detectable formaldehyde-specific IgE.
Total IgE elevation and nonspecific assay binding may affect interpretation; very high total IgE can contribute to false-positive specific IgE results.
Assay platforms, allergen preparations, reporting units, and decision thresholds may differ. Results from different methods should not be compared directly.
Published human evidence indicates that formaldehyde-specific IgE is uncommon. In one study, it was detected in only 1 of 86 exposed individuals, and in another it was detected in 2 of 155 children.